1185428-32-3

Basic information

• Product Name: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde
• Synonyms: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde;2-broMo-5h-pyrrolo[2,3-b]pyrazine-7-carbaldehyde
• CAS NO: 1185428-32-3
• Molecular Formula: C₇H₄BrN₃O
• Molecular Weight: 226.03016
• Mol File: 1185428-32-3.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde(1185428-32-3)
• EPA Substance Registry System: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde(1185428-32-3)

Safety Data

• Hazardous Substances Data: 1185428-32-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde is a chemical compound that belongs to the class of organic compounds known as pyrrolopyrazines. Pyrrolopyrazines are compounds containing a pyrrolopyrazine ring, which is a nine-member aromatic heterocycle made up of two pyrrole rings sharing a nitrogen atom. This specific chemical, with the molecular formula C8H5BrN2O, could potentially be used in the pharmaceutical or chemical industry, possibly as an intermediate in the synthesis of other compounds or as a reagent. Professional handling is required due to its synthetic and reactive nature. Details regarding its toxicity, environmental impact, and safety measures are not typically available in common databases, indicating that its use may not be widespread.

Upstream product

• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 
• 1334674-87-1 (2-bromo-5-hydroxymethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol 
• 1334674-88-2 (2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol 
• 76-05-1 trifluoroacetic acid 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 1185428-34-5 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo-[2,3-b]pyrazine-7-carbaldehyde 
• 1334675-22-7 2-phenoxy-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde 
• 1334675-23-8 2-phenoxy-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid 
• 1334674-52-0 2-[1-(2,5-Difluoro-phenyl)-1H-imidazol-4-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]amide 
• 1334675-75-0 2-[1-(2,5-difluoro-phenyl)-1H-imidazol-4-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde 
• 1334675-76-1 2-[1-(2,5-difluoro-phenyl)-1H-imidazol-4-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid 
• 1334673-38-9 2-phenoxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-methyl-1-(pyrrolidine-1-carbonyl)propyl]amide 
• 1334673-85-6 2-cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxy-4-phenylpiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 
• 1334674-10-0 2-cyclohexyloxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanopiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 
• 1334674-79-1 2-(2-methyl-1-phenyl-1H-imidazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-cyclopropyl-2-oxoethyl]amide 
• 1334674-80-4 2-(4-trifluoromethylphenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-cyclopropyl-2-oxoethyl]amide 
• 1334675-19-2 2-cyclopropyl-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxy-4-phenylpiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 
• 1334675-24-9 2-phenoxy-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-methyl-1-(pyrrolidine-1-carbonyl)propyl]amide 
• 1334675-71-6 2-(2-methyl-1-phenyl-1H-imidazol-4-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-cyclopropyl-2-oxoethyl]amide 

Relevant articles and documents

3-amido pyrrolopyrazine JAK kinase inhibitors: Development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models

The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cycl

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3- b]pyrazinyl,and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides,and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention

Its use as an inhibitor and JAK and SYK deriv. pyrroropyrazine

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R2, R3, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.